ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

ZVSA ZyVersa Therapeutics Inc

5.74
0.00 (0.00%)
시간외 단일가
최종 업데이트: 17:21:00
15분 지연
기업명 주식 심볼 시장 주식 타입
ZyVersa Therapeutics Inc ZVSA 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.00 0.00% 5.74 17:21:00
개장가 저가 고가 종가 전일 종가
5.74
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
29/04/202420:57GLOBEZyVersa Therapeutics Announces Publication Reinforcing the..
04/04/202420:57GLOBEZyVersa Therapeutics Highlights Published Data Demonstrating..
25/03/202421:17GLOBEZyVersa Therapeutics Reports Full Year 2023 Financial..
18/03/202420:57GLOBEZyVersa Therapeutics Announces IRB Approval of Phase 2a..
14/03/202420:57GLOBEZyVersa Therapeutics' CEO, Stephen C. Glover to Participate..
09/03/202407:00EDGAR2Form 8-K - Current report
09/03/202407:00EDGAR2Form PRE 14A - Other preliminary proxy statements
29/02/202421:57GLOBEZyVersa Therapeutics Generated Approximately $2.7 Million..
28/02/202421:57GLOBEZyVersa Therapeutics Highlights Data from Review Article..
22/02/202421:47GLOBEZyVersa Therapeutics Publishes New White Paper Detailing the..
15/02/202406:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
14/02/202421:53GLOBEZyVersa Therapeutics Highlights Review Article..
07/02/202422:02GLOBEZyVersa Therapeutics' CEO, Stephen C. Glover to Present at..
31/01/202421:57GLOBEZyVersa Therapeutics Highlights Publication Indicating That..
24/01/202421:57GLOBEZyVersa Therapeutics Announces Peer-Reviewed Article..
19/01/202420:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
17/01/202421:52GLOBEZyVersa Therapeutics Highlights Peer-Reviewed Article..
10/01/202422:06GLOBEZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on..
04/01/202421:50GLOBEZyVersa Therapeutics Announces Equity Research Coverage..
03/01/202422:07GLOBEZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter..
23/12/202306:45EDGAR2Form 8-K - Current report
18/12/202322:12GLOBEZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate..
14/12/202321:01GLOBEZyVersa Therapeutics Engages CRO, George Clinical, for Phase..
12/12/202306:30EDGAR2Form 8-K - Current report
09/12/202306:44EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
08/12/202301:20GLOBEZyVersa Therapeutics Announces Publication Demonstrating..
07/12/202314:15EDGAR2Form EFFECT - Notice of Effectiveness
07/12/202311:00GLOBEZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million..
06/12/202321:20GLOBEZyVersa Therapeutics Announces Publication Showing AIM2 and..
01/12/202301:45EDGAR2Form 8-K - Current report
01/12/202301:30GLOBEZyVersa Therapeutics, Inc. Announces Reverse Stock Split and..
21/11/202307:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/11/202306:15EDGAR2Form 8-K - Current report
15/11/202306:35GLOBEZyVersa Therapeutics Reports Third Quarter 2023 Corporate..
09/11/202321:35GLOBEZyVersa Therapeutics Announces Article Published in..
06/11/202321:05GLOBEZyVersa Therapeutics Announces Article in Peer-Reviewed..
03/11/202305:37EDGAR2Form 8-K - Current report
01/11/202321:07GLOBEZyVersa Therapeutics Announces Publication in Molecular..
25/10/202319:50GLOBEZyVersa Therapeutics Announces Research Published in the..
25/10/202305:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/10/202320:05GLOBEZyVersa Therapeutics Announces a Publication in the..
18/10/202305:15EDGAR2Form S-1/A - General form for registration of securities..
11/10/202320:05GLOBEZyVersa Therapeutics Announces Peer-Reviewed Publication in..
04/10/202320:05GLOBEZyVersa Therapeutics Announces New Peer-Reviewed Publication..
27/09/202320:07GLOBEZyVersa Therapeutics' CEO, Stephen C. Glover to Participate..
22/09/202319:35GLOBEZyVersa Therapeutics Announces Research Published in The..
21/09/202306:15EDGAR2Form 8-K/A - Current report: [Amend]
14/09/202320:00EDGAR2Form 8-K - Current report
14/09/202305:57EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
14/09/202305:40EDGAR2Form DEF 14A - Other definitive proxy statements

최근 히스토리

Delayed Upgrade Clock